X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Phase 2 Active not recruiting 27 enrolled Fudan University Betta Pharmaceuticals Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese ALK-positive NSCLC patients with brain metastases, eligible patients will be enrolled with objective responses being primary outcome measures.

Timeline

Start: 2019-04-12
Primary completion: 2025-06-30
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ensartinib	Small molecule	225 mg	Oral

X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Summary

Timeline

Drugs

Indications